Within the medical demo knowledge with Xyrem in narcolepsy/cataplexy patients at therapeutic doses, two people claimed stress and anxiety and just one noted insomnia pursuing abrupt discontinuation for the termination with the clinical trial; in the two clients with stress, the frequency of cataplexy experienced improved markedly at the same time.A